Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of disitamab vedotin neoadjuvant monotherapy for HER2-positive stage T3-T4a bladder cancer
ChiCTR2400086207Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Guangdong Medical University
- Start
- Jun 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in bladder cancer and transitional cell carcinoma (TCC), sponsored by The Affiliated Hospital of Guangdong Medical University. Primary endpoint: Pathology downgrade rate. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2400086207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086207.